Mike Evans, Ph.D., is now nonexecutive chairman for TAP Biosystems. Dr. Evans had been a nonexecutive director of TAP since 2005 and has worked in the life science industry for over 20 years with companies including GE Healthcare and Oxford Gene Technology.
Jim Macemon joined nanoMR as vp, product development…Akorn appointed Adrienne Graves, Ph.D., to its board of directors…Galectin Therapeutics appointed Thomas A. McGauley as acting CFO…Alkermes appointed Mark Stejbach as CCO…Bogdan Dziurzynski, Ph.D., joined Anthera Pharmaceuticals’ board of directors…Pacgen appointed Peter Sheu as COO…S1 Pharmaceuticals appointed Robert E. Pyke, M.D., Ph.D., as CMO and added Molly A. Katz, M.D., to its scientific advisory board of directors…Cubist Pharmaceuticals added Jane E. Henney, M.D., to its board of directors.
CTI Clinical Trial and Consulting Services hired Melanie A. Bruno, Ph.D., as vp, clinical trial operations. Dr. Bruno formerly served at Kendle as vp, global regulatory and medical affairs; vp, global regulatory, site, and medical affairs; and vp, global regulatory and quality.
Infinity Pharmaceuticals hired Gwen A. Fyfe, M.D., and Norman C. Selby as independent members of its board of directors…International Stem Cell elected James Berglund, Ph.D., to its board of directors…MolecularHealth named Larry Lesko, Ph.D., scientific advisor…ImmunoCellular Therapeutics elected Richard Chin, M.D., to its board of directors…Novavax appointed John A. Herrmann III vp and general counsel…SciFluor Life Sciences appointed Mark Duggan, Ph.D., as vp, scientific operations; Scott Edwards, Ph.D., as vp and general manager; and Naina Bhasin, Ph.D., as vp, business development.
Tetra Logic Pharmaceuticals appointed C. Glenn Begley, Ph.D., as svp, R&D. Dr. Begley was previously vp and global head of hematology at Amgen. In his new position, Dr. Begley will be overseeing translational studies to support birinapant, a Smac mimetic drug candidate.
Agenus appointed Shalini Sharp to its board of directors…Galena Biopharma added Hope S. Rugo, M.D., to the company’s scientific advisory board…Louis E. Grever joined IntegenX’ board of directors…Stemline Therapeutics added Kevin Buchi to its board of directors…AnaptysBio added David L. Lacey, M.D., and Michael Gallatin, Ph.D., to its therapeutic advisory board…ImmusanT hired Patrick H. Griffin, M.D., as CMO and svp, development and Michelle Hipwood as director of finance and operations…Thermo Fisher Scientific appointed David M. Sabatini, M.D., Ph.D., to its scientific advisory board.
Constellation Pharmaceuticals hired Keith E. Dionne, Ph.D., as president and CEO. Dr. Dionne previously worked at Third Rock Ventures as an entrepreneur-in-residence. He has also served as CEO at Surface Logix and, prior to that, president and CEO of Alantos Pharmaceuticals.
Chemgen Pharma International hired Debasis Das, Ph.D., as general manager of business development…Seattle Genetics appointed Nancy A. Simonian, M.D., to its board of directors…Dongmei Su, Ph.D., is now a director and Jing Lou M.D., Ph.D., now chairman of 3SBio’s board of directors…Genesis Biopharma named Hans E. Bishop executive chairman of its board of directors…Synta Pharmaceuticals appointed George Farmer, Ph.D., as vp, corporate development…John P. Shannon joined Durata Therapeutics as CCO…Laureate Biopharmaceutical Services appointed Lisa Cozza as vp, business development.
Michael J. Holston is now chief ethics and compliance officer at Merck. Holston was previously evp and general counsel for Hewlett-Packard. Prior to that, he was a partner in the litigation practice at Morgan, Lewis, & Bockius.
MiniVax added Gordon Brown, Ph.D., to its scientific advisory board…Islet Sciences appointed Paul Johnson, M.D.; Jonathan Lakey, Ph.D.; Steven Paraskevas, M.D., Ph.D.; Miguel Riella, M.D., Ph.D.; Jerry L. Nadler, M.D.; and Christian Mende, M.D., to its new scientific advisory board…Richard M. LeLacheur, Ph.D., joined Agilux Laboratories as senior director, bioanalytical operations.